{
    "clinical_study": {
        "@rank": "51873", 
        "arm_group": {
            "arm_group_label": "Treatment (radiation therapy/chemotherapy, stem cell infusion)", 
            "arm_group_type": "Experimental", 
            "description": "BLOCK I: Patients receive etoposide IV over 1-2 hours and ifosfamide IV over 1 hour on days 1-5. Patients also undergo WB-MRI-guided intensity-modulated radiation therapy BID, 5 days a week, for approximately 4 weeks. Patients may also undergo 4 fractions of SRT QOD, 3-8 fractions of SBRT QOD, or 10 fractions of 3D RT daily to sites of metastatic disease.\nBLOCK II: Patients receive high-dose chemotherapy comprising topotecan hydrochloride IV continuously over 24 hours on days -8 to -4, busulfan IV over 2 hours every 6 hours on days -8 to -4, and melphalan IV over 30 minutes on days -3 and -2. Patients undergo autologous peripheral blood or bone marrow stem cell infusion on day 0."
        }, 
        "brief_summary": {
            "textblock": "This pilot clinical trial studies whole-body radiation therapy, systemic chemotherapy, and\n      high-dose chemotherapy followed by stem cell rescue in treating patients with poor-risk\n      Ewing sarcoma. Giving chemotherapy and radiation therapy before a peripheral blood stem cell\n      or bone marrow transplant stops the growth of tumor cells by stopping them from dividing or\n      killing them. After treatment, stem cells are collected from the patient's blood and stored.\n      More chemotherapy is given to prepare the bone marrow for stem cell transplant. The stem\n      cells are then returned to the patient to replace the blood-forming cells that were\n      destroyed by the chemotherapy"
        }, 
        "brief_title": "Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma", 
        "condition": [
            "Adult Supratentorial Primitive Neuroectodermal Tumor (PNET)", 
            "Ewing Sarcoma of Bone", 
            "Extraosseous Ewing Sarcoma", 
            "Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor", 
            "Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor", 
            "Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor", 
            "Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neuroectodermal Tumors", 
                "Neuroectodermal Tumors, Primitive", 
                "Sarcoma, Ewing's", 
                "Neuroectodermal Tumors, Primitive, Peripheral", 
                "Sarcoma", 
                "Osteosarcoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To assess the safety and feasibility of whole-body magnetic resonance imaging\n      (WB-MRI)-guided intensity modulated radiation therapy delivered concurrently with systemic\n      chemotherapy to sites of metastatic disease in patients with relapsed, refractory and/or\n      poor risk Ewing sarcoma.\n\n      II. To assess the safety and feasibility of a novel consolidation regimen consisting of\n      busulfan, melphalan and topotecan (topotecan hydrochloride) followed by autologous stem cell\n      rescue, to be administered immediately after completion of radiation therapy in patients\n      with relapsed, refractory and/or poor risk Ewing sarcoma.\n\n      SECONDARY OBJECTIVES:\n\n      I. To characterize the timing of myeloid and platelet engraftment.\n\n      II. To estimate the overall and progression free survival probabilities.\n\n      III. To estimate the cumulative incidence of relapse/progression and non-relapse related\n      mortality.\n\n      IV. To report the overall response rate (overall response rate [ORR]: complete response\n      [CR]+partial response [PR]) and response duration.\n\n      V. To descriptively compare the diagnostic imaging results (number and site of bone\n      metastases) of whole-body MR imaging to those obtained by skeletal scintigraphy.\n\n      OUTLINE:\n\n      BLOCK I: Patients receive etoposide intravenously (IV) over 1-2 hours and ifosfamide IV over\n      1 hour on days 1-5. Patients also undergo WB-MRI-guided intensity-modulated radiation\n      therapy twice daily (BID), 5 days a week, for approximately 4 weeks. Patients may also\n      undergo 4 fractions of stereotactic radiation therapy (SRT) every other day (QOD), 3-8\n      fractions of stereotactic body radiation therapy (SBRT) QOD, or 10 fractions of\n      3-dimensional radiation therapy (3D RT) daily to sites of metastatic disease.\n\n      BLOCK II: Patients receive high-dose chemotherapy comprising topotecan hydrochloride IV\n      continuously over 24 hours on days -8 to -4, busulfan IV over 2 hours every 6 hours on days\n      -8 to -4, and melphalan IV over 30 minutes on days -3 and -2. Patients undergo autologous\n      peripheral blood or bone marrow stem cell infusion on day 0.\n\n      After the stem cell infusion, patients are followed up for up to 5 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with relapsed Ewing's sarcoma or primitive neuroectodermal tumor (PNET) with\n             bony/soft tissue metastasis who achieved at least partial response (PR) to\n             chemotherapy, surgery or radiotherapy\n\n          -  Newly diagnosed patients with metastatic disease to the bones: patients with\n             metastatic Ewing's or metastatic PNET who achieved at least partial response (PR) to\n             chemotherapy, surgery or radiotherapy are eligible\n\n          -  Ewing's sarcoma/PNET histology confirmed by Anatomic Pathology Department;\n             histological confirmation of relapse is highly recommended but not mandatory\n\n          -  Patients must have documented at least partial response (PR) to previous therapy\n             regimens; previous modalities may include surgery, chemotherapy, or radiation\n             therapy; radiation must not include lung fields; only patients in CR or PR at the\n             primary site will be eligible\n\n          -  Patients must have metastatic/recurrent disease identified by WB-MRI at the time of\n             study entry; intensity-modulated radiation therapy (IMRT) can be delivered per\n             protocol guidelines to at least one but not more than five primary/metastatic sites\n\n          -  Patients must have Karnofsky performance status > 60% OR Lansky performance status >\n             50% for patients younger than 16 years old\n\n          -  Women of child-bearing potential and men must agree to use adequate contraception\n             (hormonal or barrier method of birth control or abstinence) prior to study entry and\n             for six months following duration of study participation; should a woman become\n             pregnant or suspect that she is pregnant while participating on the trial, she should\n             inform her treating physician immediately\n\n          -  Adequate number of autologous stem cells collected and cryopreserved prior to\n             starting the study treatment\n\n          -  Creatinine clearance (12 or 24 hour urine collection) or glomerular filtration rate\n             (GFR) > 60 ml/min/1.73 m^2\n\n          -  Ejection fraction > 50% by echocardiogram or multiple gated acquisition (MUGA)\n\n          -  Bilirubin < 2 x upper limit of normal\n\n          -  Serum glutamic oxalo-acetic transaminase (SGOT) and serum glutamate pyruvate\n             transaminase (SGPT) < 5 x upper limit of normal\n\n          -  Platelet count > 50,000/ul\n\n          -  Absolute granulocyte count >= 750/ul\n\n          -  Forced expiratory volume in one second (FEV1) > 2 liters adults (older than 16 years)\n\n          -  Room air arterial oxygen pressure (PaO2) > 70 mm Hg adults (older than 16 years)\n\n          -  Room air partial pressure of carbon dioxide (PaCO2) < 42 mm Hg adults (older than 16\n             years)\n\n          -  Diffusion capacity of carbon monoxide (DLCO) > 50% predicted\n\n          -  If unable to cooperate with pulmonary function testing due to young age, then pulse\n             oximetry >= 94% children (younger than 16 years)\n\n          -  Pretreatment tests must have been performed within 4 weeks prior to initiation of\n             protocol treatment\n\n          -  No other medical and/or psychosocial problems which, in the opinion of the primary\n             physician or principal investigator, would place the patient at unacceptable risk\n             from this regimen\n\n          -  Greater than 2 week period of recovery from prior modality used to control primary or\n             recurrent site\n\n          -  All subjects or their legal guardians must have the ability to understand and the\n             willingness to sign a written informed consent\n\n        Exclusion Criteria:\n\n          -  Patients should not have any uncontrolled illness including ongoing or active\n             infection\n\n          -  Patients may not be receiving any other investigational agents, concurrent biological\n             agents, or chemotherapy\n\n          -  Patients must not have received prior chemotherapy or radiation within 2 weeks before\n             study enrollment, and those who have not recovered from the adverse events due to\n             agents administered more than 2 weeks earlier are excluded\n\n          -  Pregnant women are excluded from this study; breastfeeding should be discontinued if\n             the mother is treated on this study\n\n          -  Patients with other active malignancies are ineligible for this study\n\n          -  Patients with prior treatment with myeloablative therapy are excluded\n\n          -  Karnofsky performance status < 60% or Lansky performance status < 50% for patients\n             younger than 16 years old\n\n          -  Patients who require irradiation to more than 5 disease sites are excluded\n\n          -  Subjects who, in the opinion of the investigator, may not be able to comply with the\n             safety monitoring requirements of the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "40 Years", 
            "minimum_age": "6 Months"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01795430", 
            "org_study_id": "12391", 
            "secondary_id": "NCI-2013-00439"
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (radiation therapy/chemotherapy, stem cell infusion)", 
                "description": "Given IV", 
                "intervention_name": "etoposide", 
                "intervention_type": "Drug", 
                "other_name": [
                    "EPEG", 
                    "VP-16", 
                    "VP-16-213"
                ]
            }, 
            {
                "arm_group_label": "Treatment (radiation therapy/chemotherapy, stem cell infusion)", 
                "description": "Given IV", 
                "intervention_name": "ifosfamide", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Cyfos", 
                    "Holoxan", 
                    "IFF", 
                    "IFX", 
                    "IPP"
                ]
            }, 
            {
                "arm_group_label": "Treatment (radiation therapy/chemotherapy, stem cell infusion)", 
                "description": "Undergo WB-MRI-guided IMRT", 
                "intervention_name": "intensity-modulated radiation therapy", 
                "intervention_type": "Radiation", 
                "other_name": "IMRT"
            }, 
            {
                "arm_group_label": "Treatment (radiation therapy/chemotherapy, stem cell infusion)", 
                "description": "Given IV", 
                "intervention_name": "topotecan hydrochloride", 
                "intervention_type": "Drug", 
                "other_name": [
                    "hycamptamine", 
                    "Hycamtin", 
                    "SKF S-104864-A", 
                    "TOPO"
                ]
            }, 
            {
                "arm_group_label": "Treatment (radiation therapy/chemotherapy, stem cell infusion)", 
                "description": "Given IV", 
                "intervention_name": "busulfan", 
                "intervention_type": "Drug", 
                "other_name": [
                    "BSF", 
                    "BU", 
                    "Misulfan", 
                    "Mitosan", 
                    "Myeloleukon"
                ]
            }, 
            {
                "arm_group_label": "Treatment (radiation therapy/chemotherapy, stem cell infusion)", 
                "description": "Given IV", 
                "intervention_name": "melphalan", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Alkeran", 
                    "CB-3025", 
                    "L-PAM", 
                    "L-phenylalanine mustard", 
                    "L-Sarcolysin"
                ]
            }, 
            {
                "arm_group_label": "Treatment (radiation therapy/chemotherapy, stem cell infusion)", 
                "description": "Undergo autologous peripheral blood stem cell or bone marrow transplant", 
                "intervention_name": "autologous hematopoietic stem cell transplantation", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Treatment (radiation therapy/chemotherapy, stem cell infusion)", 
                "description": "Undergo autologous peripheral blood stem cell transplant", 
                "intervention_name": "peripheral blood stem cell transplantation", 
                "intervention_type": "Procedure", 
                "other_name": [
                    "PBPC transplantation", 
                    "PBSC transplantation", 
                    "peripheral blood progenitor cell transplantation", 
                    "transplantation, peripheral blood stem cell"
                ]
            }, 
            {
                "arm_group_label": "Treatment (radiation therapy/chemotherapy, stem cell infusion)", 
                "description": "Undergo autologous bone marrow transplant", 
                "intervention_name": "autologous bone marrow transplantation", 
                "intervention_type": "Procedure", 
                "other_name": [
                    "ABMT", 
                    "bone marrow transplantation, autologous", 
                    "transplantation, autologous bone marrow"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Busulfan", 
                "Melphalan", 
                "Ifosfamide", 
                "Isophosphamide mustard", 
                "Etoposide phosphate", 
                "Etoposide", 
                "Topotecan"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "February 11, 2014", 
        "location": {
            "contact": {
                "email": "apawlowska@coh.org", 
                "last_name": "Anna B. Pawlowska, MD", 
                "phone": "800-826-4673"
            }, 
            "facility": {
                "address": {
                    "city": "Duarte", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "91010"
                }, 
                "name": "City of Hope Medical Center"
            }, 
            "investigator": {
                "last_name": "Anna B. Pawlowska", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Pilot Study of Whole-body MRI-guided Intensity Modulated Radiation Therapy Combined With Systemic Chemotherapy Followed by High-Dose Chemotherapy With Busulfan, Melphalan and Topotecan and Stem Cell Rescue in Patients With Poor Risk Ewing's Sarcoma", 
        "overall_official": {
            "affiliation": "City of Hope Medical Center", 
            "last_name": "Anna Pawlowska", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Toxicities will be summarized as type, severity, date of onset, duration, reversibility, and attribution.", 
            "measure": "Percentage of patients who experience grade 4-5 non-hematologic toxicities assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0", 
            "safety_issue": "Yes", 
            "time_frame": "Up to day 100 of Block II"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01795430"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Objective tumor response for all patients will be summarized, including the number and percent responding.", 
                "measure": "Overall response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST)", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years"
            }, 
            {
                "description": "PFS will be estimated using the Kaplan-Meier product-limit method; 95% confidence intervals (CIs) will be calculated using the logit transformation and the Greenwood variance estimate.", 
                "measure": "Progression-free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "Time from stem cell infusion to the first observation of disease progression or death from any cause, whichever occurs first, assessed up to 5 years"
            }, 
            {
                "description": "OS will be estimated using the Kaplan-Meier product-limit method; 95% confidence intervals (CIs) will be calculated using the logit transformation and the Greenwood variance estimate.", 
                "measure": "Overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "Time from stem cell infusion to death from any cause, assessed up to 5 years"
            }, 
            {
                "description": "Cumulative relapse incidence will be estimated treating non-relapse related death events as competing risks and, conversely, NRM will be calculated controlling for relapse as a competing risk. Cumulative incidence of NRM and relapse-related mortality will be calculated using the method of Goole et al. Cumulative incidence differences will be assessed by Gray's test.", 
                "measure": "Non-relapse mortality (NRM)", 
                "safety_issue": "No", 
                "time_frame": "Time from stem cell infusion to death event where the cause of death is not attributable to the underlying disease, assessed up to 5 years"
            }
        ], 
        "source": "City of Hope Medical Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "City of Hope Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}